Menopause and Hair Loss: What Changes, and What Helps

Hair thinning that arrives with perimenopause is usually pattern loss becoming visible, not a new disease. A 2010 review of hair loss in elderly women in the European Journal of Dermatology puts it plainly: pre-existing conditions such as androgenetic alopecia usually worsen after menopause, while some other scalp conditions ease. The part widens, the ponytail thins, and the change that made it obvious was hormonal rather than sudden.

That review also carries the warning that makes this age group different from any other on this site, and it is worth reading before anything is bought.

The one presentation that needs a doctor first

The 2010 review states that hormone investigation — specifically with regard to internal androgen-producing tumours — is indicated in postmenopausal women with androgenetic alopecia of sudden exacerbation, or with unusual features or other signs of virilisation.

In plain terms: gradual thinning that has been creeping on for years is one thing. Thinning that accelerates sharply, or arrives alongside new facial hair, a deepening voice or other masculinising changes, is a reason to be examined rather than to try a serum. That is not a common scenario, and it is exactly why it is worth naming — nobody is going to find it on a product page.

The same review lists several other conditions that show up disproportionately in this age group: frontal fibrosing alopecia, which scars; tinea capitis, an infection, observed increasingly in postmenopausal women; and hair loss from metastatic disease in women with an underlying cancer. It notes that acute or chronic telogen effluvium is "not uncommonly superimposed" on pattern loss, which is why two things can be happening at once. Hair loss after menopause, it concludes, is often multifactorial and warrants close inspection.

Why pattern loss shows up now

A 2015 review of female pattern hair loss describes it as a condition that mostly affects postmenopausal women, presenting as a diffuse thinning over the mid-frontal scalp with a frontal hairline that stays more or less intact, without inflammation or scarring. The American Academy of Dermatology's patient page agrees on the timing: for most women, it begins in midlife — in their forties, fifties or sixties.

Nothing about that means the hair was fine until menopause and then failed. Follicles miniaturise over many cycles, and what changes around menopause is how far that process has got and how little is masking it. Why a part widens covers the mechanism and the four conditions that imitate it.

What the evidence for treating it actually is

Here is the awkward part. The best trial evidence for topical minoxidil in women — the 48-week randomised placebo-controlled trial of 381 women that underpins most claims made to women — enrolled women aged 18 to 49. The second trial, of 113 women comparing once-daily 5% foam with twice-daily 2% solution, was in women with androgenetic alopecia without an upper age cut-off in its title, but it is a single 24-week study.

So the strongest evidence in women is largely evidence in younger women, applied by clinicians to older ones on reasonable grounds. That is normal in medicine and it is not a scandal; it is simply not the same as a trial in postmenopausal women, and you will not see that distinction drawn on a sales page.

Two prescription routes come up in this age group:

• Spironolactone, an anti-androgen the AAD lists as a common treatment for female pattern hair loss. A 2023 systematic review and meta-analysis reported improvement in 56.6% of patients overall, and no improvement or only modest improvement in 37.8%, with scalp itching or scurf (18.9%), menstrual disturbance (11.9%) and facial hair growth (6.9%) among the adverse effects reported in at least two studies.
• Finasteride, whose own label reports a 12-month study of 137 postmenopausal women in which effectiveness could not be demonstrated on any outcome against placebo. That is the manufacturer's own data, and it is the single most useful fact in this article for anyone about to be offered it. What women should know about finasteride covers the rest.

Neither is prescribed by a website, and neither is dosed here.

Where menopause-branded products sit

Supplements sold for hair through menopause are the busiest category in this space. The largest brand sells a formula aimed at women 45 and over, at $88 bought one month at a time or $79 on the monthly plan, and there is a randomised, double-blind, placebo-controlled trial behind that specific formula — published in 2021, 40 women on the product and 30 on placebo over six months, reporting increased hair counts at day 90 and day 180 — with a co-author who is one of the company's own founders and funding from the company. Our evidence-graded review of the women's range works through what that does and does not establish.

Shampoos and serums marketed for menopausal hair are cosmetics: no approved hair-loss claim, and percentages that generally come from consumer perception studies rather than trials. Bought as cosmetics, they are fine. Bought as treatment, they displace treatment.

Hormone therapy is a different conversation

Women ask, reasonably, whether hormone therapy will help their hair. This site does not answer that, for a specific reason: menopausal hormone therapy is prescribed on the basis of symptoms, history and risk, and its effects on hair are neither its indication nor a settled matter in the literature we could verify at source. A page with no clinician behind it should not be the thing that tips that decision. Ask the person managing your menopause care, and ask them the hair question directly — it is a legitimate thing to raise.

A reasonable order of operations

1. If the thinning accelerated suddenly, or came with other masculinising changes, get examined before anything else.
2. If the scalp is painful, scaling or visibly scarring, that is also a doctor, quickly.
3. If it is gradual, ask for a diagnosis, and ask whether bloods are worth doing in your case.
4. Then, and only then, choose from the routes that have been tested — starting with the one with randomised trials in women behind it.

The full list, with the evidence grade, the price and the cautions for each, is on every hair-loss treatment for women, graded by what was tested in women. It is deliberately ordered by evidence rather than by what any of it pays.